• First patient recruited for Phase IIa clinical trial
• EUR 2.4 million in non-dilutive funding secured from Bpifrance
• Final results of Phase I study expected in Q1 2027
Dijon, France, November 16, 2026 — EktaH, a clinical-stage biotechnology company developing first-in-class oral therapies for obesity and metabolic diseases, today announced that it has advanced its lead compound NKS-3 into Phase II clinical development for the treatment of obesity. The first patient has been recruited for the exploratory Phase IIa SERENITY-1 study (NCT07882654) in Tunisia.
In
parallel, EktaH has secured EUR 2.4 million in non-dilutive funding from
Bpifrance to support further clinical development, including a larger Phase II
study planned in France.
Exploratory
Phase IIa SERENITY-1 Study Underway in Tunisia SERENITY-1
is a randomized, single-blind, placebo-controlled exploratory Phase IIa study
evaluating NKS-3 in adults with obesity. The study is being conducted at the
Institut National de Nutrition de Tunis and plans to enroll approximately 31
participants, randomized 2:1 to NKS-3 or matching placebo. The first patient
has been enrolled. Participants will self-administer study treatment for 90
days.
The
primary endpoint is percent change in body weight from baseline to Day 90.
Secondary and exploratory assessments include changes in oro-sensory
sensitivity to linoleic acid, safety and tolerability, and the composition of
weight loss, including changes in fat mass and skeletal muscle mass. The NKS-3
regimen is 7.5 mg twice daily, corresponding to a total daily dose of 15 mg.
Topline study results are expected in Q1 2027.
Bpifrance
Funding Supports Next Clinical Development Steps The
Bpifrance program supports key development milestones for NKS-3, including a
90-day toxicology study, chemistry, manufacturing and controls (CMC)
activities, and Phase II clinical development. The funding will be disbursed in
phases, subject to predefined annual stage gates and achievement of development
and regulatory milestones. The non-dilutive funding package comprises equal parts grant
funding and reimbursable advances.
The
expanded Phase II clinical program will evaluate a new formulation of NKS-3 in
two key settings: as monotherapy for weight loss and as maintenance
treatment following GLP-1 discontinuation.
The
planned multicenter, randomized, dose-finding trials will evaluate several
dosing regimens to assess NKS-3’s potential to reduce body weight and fat mass
while preserving lean mass. The program will also investigate its potential to
maintain weight loss after GLP-1 treatment ends, supported by preliminary
preclinical findings. These potential benefits remain to be established in
clinical trials. Within the broader program, a planned study is expected to
enroll approximately 100 adults with obesity, comparing two NKS-3 dosing
regimens with placebo in a double-blind, randomized trial. Treatment will last
12 weeks, followed by a 12-week off-treatment follow-up. Final study designs
remain subject to applicable regulatory and ethics approvals.
EktaH
aims to submit the Clinical Trial Application in early 2027 and to enroll the
first patient in the second half of 2027.
“Advancing
NKS-3 into Phase II clinical development marks an important milestone for
EktaH,” said Xavier Boidevezi, CEO and Co-founder of EktaH. “With the
SERENITY-1 study now recruiting patients in Tunisia and Bpifrance funding
supporting preparations for a larger Phase II study in France, we are
progressing a clinical development program designed to further evaluate the
efficacy, safety and therapeutic potential of our differentiated approach to
obesity treatment.”
Final
Results of Phase I Study Expected in Q1 2027 The
Company is finalizing its Phase I study and expects to lock the database by the
end of November 2026, with final results and the Clinical Study Report expected
in Q1 2027. The randomized, single-blind, placebo-controlled, single-center
study enrolled 120 adults with obesity across single- and multiple-ascending-dose
cohorts to evaluate NKS-3 and NKS-5, two modified linoleic acids, including
their effects on weight and oral fat sensitivity. Preliminary data from 22
participants treated with NKS-3 for 30 days show no serious adverse events
considered related to NKS-3 reported to date. The complete analysis will
provide a comprehensive assessment of safety and preliminary efficacy and
inform the planned Phase II program.
NKS-3:
Restoring Physiological Satiety Signaling, Potentially Reducing
Post-Semaglutide Weight Rebound and Providing Potent Anti-Inflammatory Activity NKS-3
is an orally administered modified fatty acid molecule designed to reactivate
the fat taste receptors CD36 and GPR120 in the tongue epithelium, which are
downregulated in many individuals with obesity.
The
compound is designed to restore normal function to these receptors, triggering
the body’s own natural release of satiety hormones including GLP-1,
cholecystokinin (CCK), and peptide YY (PYY), and reducing food intake through
the body’s endogenous signaling without the need for exogenous hormone
administration.
Earlier
preclinical studies showed approximately 50% less weight rebound in
diet-induced obese mice receiving NKS-3 after discontinuation of semaglutide
compared with control animals, while preserving lean body mass. These data
support the potential development of NKS-3 both as a standalone obesity
treatment and as a maintenance approach following GLP-1 therapy.
In
addition, NKS-3 demonstrated potent anti-inflammatory activity in multiple
experimental models, with significant reductions in key pro-inflammatory
cytokines and modulation of central inflammatory signaling pathways. These
findings support the potential of EktaH’s approach to address the broader
inflammatory component of obesity and metabolic diseases and represent an
additional pipeline opportunity.
About
EktaH EktaH is a clinical-stage
biotechnology company developing first-in-class oral therapies for obesity and
metabolic diseases. The Company’s proprietary platform targets fat taste
receptors (CD36 and GPR120) — a novel mechanism that naturally stimulates the
body’s endogenous release of satiety hormones including GLP-1, CCK, and PYY,
without the need for exogenous hormone administration. EktaH
holds worldwide exclusive licenses on its core fat taste receptor technology
(patents through 2044), with confirmed freedom-to-operate in Europe and the
United States. The Company’s pipeline includes two lead molecules (NKS-3 and
NKS-5) for obesity, an anti-inflammatory program, and next-generation agonists
in early development. EktaH is ISO 9001:2015 certified and is supported by an
international Scientific Advisory Board. Founded in 2021, EktaH is
headquartered in Dijon, France.
Investor
Contact Xavier
Boidevezi, CEO and Co-founder xboidevezi@ektah.fr
| +33 6 33 41 42 31 EktaH
SAS | 6 boulevard Gabriel, 21000 Dijon, France
Media Contact akampion Ines-Regina
Buth / Francina Agosti Tel. +49 30 23
63 27 68
Forward-Looking Statements This press release contains forward-looking statements within
the meaning of applicable securities laws. These statements involve known and
unknown risks, uncertainties, and other factors that may cause actual results
to differ materially from those expressed or implied. Forward-looking
statements include, without limitation, statements regarding the potential
therapeutic benefits of NKS-3, plans for clinical development, and expected
timelines. EktaH undertakes no obligation to update forward-looking statements
to reflect events or circumstances after the date of this release.